GENETIC CHEMISTRY Trademark
Trademark Overview
On Friday, December 22, 2023, a trademark application was filed for GENETIC CHEMISTRY with the United States Patent and Trademark Office. The USPTO has given the GENETIC CHEMISTRY trademark a serial number of 98327493. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Wednesday, October 30, 2024. This trademark is owned by Empress Therapeutics, Inc.. The GENETIC CHEMISTRY trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceuticals, namely, pharmaceutical preparations for treatment of cancer, inflammatory diseases and disorders, immune system-related diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, and neurodegenerative diseases and disorders; therapeutics in the nature of oral products, injectables, topical products, inhalation products, ophthalmic products, otic products, nasal products, rectal products, vaginal products, implants, infusions, transdermal systems, and oral thin films; therapeutic pharmaceuticals for the treatment of cancer, inflammatory diseases and disorders, immune system-related diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, and neurodegenerative diseases and disorders
Pharmaceutical research and development; scientific and medical research and development; technical scientific research consultation and product development for others in the field of biotechnology and the development of pharmaceuticals and microbial products; research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; platform as a service (PAAS) featuring computer software platforms for research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; drug discovery platform
General Information
| Serial Number | 98327493 |
| Word Mark | GENETIC CHEMISTRY |
| Filing Date | Friday, December 22, 2023 |
| Status | 645 - FINAL REFUSAL - MAILED |
| Status Date | Wednesday, October 30, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceuticals, namely, pharmaceutical preparations for treatment of cancer, inflammatory diseases and disorders, immune system-related diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, and neurodegenerative diseases and disorders; therapeutics in the nature of oral products, injectables, topical products, inhalation products, ophthalmic products, otic products, nasal products, rectal products, vaginal products, implants, infusions, transdermal systems, and oral thin films; therapeutic pharmaceuticals for the treatment of cancer, inflammatory diseases and disorders, immune system-related diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, and neurodegenerative diseases and disorders |
| Goods and Services | Pharmaceutical research and development; scientific and medical research and development; technical scientific research consultation and product development for others in the field of biotechnology and the development of pharmaceuticals and microbial products; research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; platform as a service (PAAS) featuring computer software platforms for research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; drug discovery platform |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, April 3, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, October 28, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Empress Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02142 |
Trademark Events
| Event Date | Event Description |
| Friday, December 22, 2023 | NEW APPLICATION ENTERED |
| Thursday, April 4, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Sunday, July 28, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sunday, July 28, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, July 24, 2024 | ASSIGNED TO EXAMINER |
| Sunday, July 28, 2024 | NON-FINAL ACTION WRITTEN |
| Monday, October 28, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, October 28, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, October 28, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, October 30, 2024 | FINAL REFUSAL WRITTEN |
| Wednesday, October 30, 2024 | FINAL REFUSAL E-MAILED |
| Wednesday, October 30, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
